The Hematology Research Training Program at the University of Washington is designed to provide intensive post-doctoral research training in investigative hematology. The program emphasizes cell and molecular biology, with particular strengths in: stem cells and hematopoiesis, cell and gene therapy, platelets and hemostasis, vascular biology, hematologic malignancies, cancer biology, and hematopoietic cell transplantation. Program faculty includes established investigators with strong independent research programs from both basic science and clinical departments at the University of Washington, Fred Hutchinson Cancer Research Center, and nearby affiliated institutions. The goal of the Training Program is to develop the research, presentation, and fund-raising skills that trainees will need to establish independent research careers, and to train future leaders in the field of research hematology. Trainees have MD, MD/PhD or PhD degrees. Many have completed clinical training in hematology, but others are basic researchers wishing to work in the field. Trainees are chosen through an application process and interactions with program faculty. They obtain laboratory experience by working with a mentor, and are assisted in laboratory techniques, publishing papers, presentation skills, and acquiring independent grant support. Trainees typically receive 2 years of funding from the Program, but often continue their training longer under separate funding mechanisms. Training progress is monitored by the faculty mentor, a separate faculty advisor, the Program Directors, and the Division of Hematology faculty through regular research presentations and meetings with each trainee. The main strengths of the Program include: diverse research opportunities, a qualified senior faculty, and a long track record, spanning over four decades of graduates obtaining junior faculty positions and becoming independent and distinguished investigators.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007093-40
Application #
8689132
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Chang, Henry
Project Start
1975-07-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
40
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98195
Samuelson, Bethany T; Cuker, Adam; Siegal, Deborah M et al. (2017) Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest 151:127-138
Li, Ang; Davis, Chris; Wu, Qian et al. (2017) Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. Blood Adv 1:707-714
Samuelson, Bethany T; Cuker, Adam (2017) Measurement and reversal of the direct oral anticoagulants. Blood Rev 31:77-84
Halpern, Anna B; Culakova, Eva; Walter, Roland B et al. (2017) Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. JAMA Oncol 3:374-381
Samuelson Bannow, B T; Walter, R B; Gernsheimer, T B et al. (2017) Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. J Thromb Thrombolysis 44:442-447
Gornalusse, Germán G; Hirata, Roli K; Funk, Sarah E et al. (2017) HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol 35:765-772
Godwin, Colin D; McDonald, George B; Walter, Roland B (2017) Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 129:2330-2332
Halpern, A B; Othus, M; Huebner, E M et al. (2017) Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia 31:2560-2567
Buckley, Sarah A; Wood, Brent L; Othus, Megan et al. (2017) Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102:865-873
Cowan, Andrew J; Stevenson, Philip A; Cassaday, Ryan D et al. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant 22:380-385

Showing the most recent 10 out of 86 publications